M&G plc’s BioCryst Pharmaceuticals BCRX Stock Holding History

M&G plc’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,046,016	Closed	-$9.41M	–	380
2025 Q2	$9.41M	Buy	+1,046,016	New	+$9.74M	0.05%	216

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M&G plc's BCRX Position: Q3 2025 in Review

M&G plc sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 1,046,016 shares — an estimated $9.41M sold.

M&G plc first reported a position in BCRX in Q2 2025 and held it in 1 quarter. The position peaked at $9.41M in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

M&G plc reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
M&G plc sold 1,046,016 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $9.41M.
M&G plc first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 1 quarter.
M&G plc's BioCryst Pharmaceuticals position peaked at $9.41M in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on M&G plc's 13F filing for Q3 2025, filed 7 Nov 2025.